Imaging and Tissue Biomarkers in the Treatment of Brain Tumors

脑肿瘤治疗中的成像和组织生物标志物

• 批准号: 7880264
• 负责人: MITCHEL S. BERGER
• 金额: $ 218.55万
• 依托单位: UNIVERSITY OF CALIFORNIA, SAN FRANCISCO
• 依托单位国家: 美国
• 财政年份: 2007
• 资助国家: 美国
• 起止时间: 2007-08-27 至 2012-06-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7880264
• 关键词: Imaging; Tissue; Biomarkers; Treatment; Brain

DESCRIPTION (provided by applicant): The overall goal is to integrate advances in technological development of physiologic neuro-imaging and tissue biomarkers in the management of patients with brain tumors and to translate this knowledge to optimize treatment. Malignant glioma is a significant clinical challenge and much effort is expended in the development of new therapeutic strategies. Although radiation therapy (XRT) prolongs survival for glioblastoma multiforme (GBM), about 30 percent of patients progress during the course of XRT and have a poor prognosis. Project 1 will study the potential of metabolic and physiologic imaging and tissue correlates to identify these patients prior to initiation of therapy and to integrate this knowledge in an individualized treatment paradigm. Patients with GBM universally progress and these recurrent tumors are heterogeneous in their behavior. Apart from patient-related prognostic factors (age and performance status), there are no biological predictors of outcome. Project 2 will study the non-invasive physiologic and metabolic parameters with tissue correlates to better understand tumor heterogeneity and biological behavior. This information should have a major impact on the selection of patients for clinical trials and the design and interpretation of results. If the physiologic imaging parameters are indeed representative of biological behavior such as angiogenesis or invasive capacity, this will have significant application in the evaluation of novel targeted therapies. New therapeutic approaches involve the interstitial delivery of agents into tumor-infiltrated brain parenchyma. Determining the extent and nature of the invasive component of infiltrative tumor is limited with standard imaging. Project 3 will study the non-invasive real-time imaging of interstitial administration of agents in animals and non-human primates to define the target for infusion and optimize delivery of therapeutic agents. The Clinical Services Core and Imaging and Tissue Correlate Core will provide services to all projects to centralize the effort for efficient and integrated management of this program project grant.

描述（由申请人提供）：总体目标是在脑肿瘤患者的管理中整合生理神经成像和组织生物标志物的技术开发进展，并将这些知识转化为优化治疗。 恶性胶质瘤是一个重大的临床挑战，许多努力都花费在新的治疗策略的发展。 虽然放射治疗（XRT）提高了多形性胶质母细胞瘤（GBM）的生存率，但约30%的患者在XRT过程中进展，预后不良。 项目1将研究代谢和生理成像以及组织相关性的潜力，以在开始治疗之前识别这些患者，并将这些知识整合到个性化治疗模式中。 GBM患者普遍进展，这些复发性肿瘤的行为是异质性的。 除了与患者相关的预后因素（年龄和体能状态）外，没有生物学预测因子。 项目2将研究与组织相关的非侵入性生理和代谢参数，以更好地了解肿瘤异质性和生物学行为。 这些信息对临床试验患者的选择以及结果的设计和解释具有重要影响。 如果生理成像参数确实代表了生物学行为，如血管生成或侵入能力，这将在新的靶向治疗的评价中具有重要的应用。 新的治疗方法包括将药物间质递送到肿瘤浸润的脑实质中。 标准影像学检查对浸润性肿瘤浸润性成分的范围和性质的确定是有限的。 项目3将研究动物和非人类灵长类动物间质给药的非侵入性实时成像，以确定输注靶点并优化治疗剂的输送。 临床服务核心和成像与组织相关核心将为所有项目提供服务，以集中精力有效和综合管理该计划项目赠款。